Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by RalphRalphon Feb 17, 2021 6:02pm
195 Views
Post# 32590752

RE:Disappointed

RE:Disappointed
Agree - management has done two bought deals at low valuations in the past 9 months - each time diluting by about 25%.  That level of dilution in 9 months is not effective management.  And they still have not been able to offload Citagenix. 
 
 Of course it strengthens their negotiating position - but it does so at immense cost to shareholders.  Each raise lowers the potential upside profit returns.


Forestview wrote: This will certainly kill the momentum, and it feels like after we left the $4 invisible wall behind, we now have one at $6.  But, I suspect this was in the works before the Nuance deal was announced, so perhaps they didnt realize the share price would be where it was, and the momentum was building.  But, it does feel like a another set back, with more dilution.  

Even though I thought the plan was to have another drug company take Otena through Phase 3, I guess they wanted to show that THEY COULD do it if they had to.  But still.  Not happy with this.  I think we will be mired in the $5.80 to $6.20 range for the foreseeable future.  


<< Previous
Bullboard Posts
Next >>